Back to news

Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement

Globe Newswire•18/11/2026•07:30 ET
0

Key Highlights

  • ➤OPTI-101 Phase 2b targets 200 adults with severe MDD; dosing expected Q1 2027
  • ➤OPTI-101 topline data expected in 2028 after randomized, double-blind trial
  • ➤OPTI-201 Phase 3 targets 100 veterans and front-line workers with PTSD in 2027
  • ➤FDA IND filings planned in 2027 for OPTI-101 and OPTI-201
  • ➤US$240,000 CEO compensation debt to be settled with 114,285 shares at US$2.10

Expert Statements

JJ Wilson, Chairman of the Board of Optimi Health Corp.

“2027 is a pivotal year for Optimi as we advance several product candidates. Our lead product candidate, OPTI-101, is naturally derived psilocybin already prescribed in Australia, with no serious adverse events reported. Subject to Health Canada approval, we expect to begin dosing in a randomized, blinded Phase 2b study, with topline data expected in 2028. OPTI-201 is expected to start Phase 3 for veterans and front-line workers, and production of our first ibogaine capsules is weeks away. We are preparing to take these programs to the U.S. Food and Drug Administration (“FDA”),”

Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028

Health Canada-cleared Phase 3 trial of OPTI-201 MDMA-assisted therapy in 100 veterans and front-line workers with PTSD expected to begin in 2027; Company plans to file a U.S. IND for OPTI-201 in addition to the proposed Canadian trial.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in